Another significant hurdle is how well microbiome research findings are translated in real-life situations. The majority of translational work to date has been focused on preclinical experiments using germ-free animals, which do not represent the animal's natural state. Nonetheless, germ-free animals have been a vital tool in microbiome research and have helped answer simple questions, such as whether behavioral traits can be transferred via fecal microbiota transplant (FMT). Germ-free mice receiving FMT from patients with irritable bowel syndrome (IBS) developed leaky intestines and produced proinflammatory metabolites, many of which are known neurotransmitters. These animals also displayed anxious behavior, and indeed anxiety and depression are often observed in IBS patients, but the pathogenesis remains elusive. Ongoing research into the brain-gut axis has also shed light on how glia cells and neurons of the brain and gut may communicate. Observations such as these can be pieced together to build a more complete picture of the complex interactions and associations.
While we should not let our interpretations and related clinical decisions be driven by the hyperboles surrounding how gut microbes might affect human health, there are some useful advances in our knowledge that allow for clinical application. Clostridium difficile infection (CDI), which most commonly occurs in individuals whose gut microbiota have been displaced as a result of antibiotic treatment, can manifest as severe diarrhea especially in those over 65 years of age. Stopping antibiotics (to allow gut microbiota to recover) or treating with CDI-specific antibiotics (e.g., vancomycin) is not always successful -and among those with treatment failure, one in three will die. FMT is a newly available treatment for relapsed CDI in the UK and USA, in which fecal microbiota from a healthy donor can alleviate diarrheal symptoms within 1-2 days for more than 90% of patients.
The paper by Zhao and colleagues suggests a housekeeping role for Bifidobacterium species in maintaining gut homeostasis and a healthy gut ecosystem. Whether or not Bifidobacterium plays an active role in the success of FMT in CDI treatment remains to be determined. But in keeping with the US NIH Precision Medicine Initiative, future research should focus on delineating the microbial subspecies that have a positive effect on CDI treatment, which would inform a better-characterized, mechanistically-defined, microbiome-targeted intervention. Although CDI is currently the only indication for which FMT is approved outside of a clinical trial, the hundreds of other ongoing FMT trials will hopefully soon yield useful and effective interventions for many other health conditions. 
EBioMedicine

Contents lists available at ScienceDirect
